Integrin-targeted molecular imaging of experimental abdominal aortic aneurysms by 18F-labeled Arg-Gly-Asp positron-emission tomography

Circulation: Cardiovascular Imaging

Volumn 6, Issue 6, 2013, Pages 950-956

  Kitagawa, Toshiro ^a,b,c   Kosuge, Hisanori ^a,b   Chang, Edwin ^a   James, Michelle L ^a   Yamamoto, Tomoaki ^a,b   Shen, Bin ^a   Chin, Frederick T ^a   Gambhir, Sanjiv S ^a,b   Dalman, Ronald L ^a,b   McConnell, Michael V ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Aneurysm; Arginyl glycyl aspartic acid; Macrophages; Positron emission tomography

Indexed keywords

ANGIOTENSIN II; APOLIPOPROTEIN E; ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID F 18; CD11B ANTIGEN; CD31 ANTIGEN; FLUORINE 18; IODINATED CONTRAST MEDIUM; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ABDOMINAL AORTA ANEURYSM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; AUTORADIOGRAPHY; CELL DENSITY; CELL DIFFERENTIATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG TARGETING; DRUG UPTAKE; ECHOGRAPHY; EX VIVO STUDY; EXPERIMENTAL CARDIOVASCULAR DISEASE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MOLECULAR IMAGING; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PET-CT SCANNER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANEURYSM; ARGINYL-GLYCYL-ASPARTIC ACID; MACROPHAGES; POSITRON-EMISSION TOMOGRAPHY;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; DIAGNOSIS, DIFFERENTIAL; DISEASE MODELS, ANIMAL; FLUORODEOXYGLUCOSE F18; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHAVBETA3; MALE; MICE; MOLECULAR IMAGING; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS;

EID: 84892149479     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.113.000234     Document Type: Article

References (28)

1. Lederle FA, Johnson GR, Wilson S.E., Chute EP, Hye RJ, Makaroun MS, Barone G.W., Bandyk D., Moneta GL, Makhoul RG The aneu-rysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med. 2000; 160:1425-1430.
2. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006; 26:987-994.
3. Lindholt JS, Vammen S, Fasting H., Henneberg EW, Heickendorff L. The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms. A preliminary study. Eur J Vasc Endovasc Surg. 2000; 20:281-285.
4. Saraff K, Babamusta F, Cassis L.A., Daugherty A. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003; 23:1621-1626.
5. Tedesco MM, Terashima M, Blankenberg F.G., Levashova Z., Spin JM, Backer MV, Backer JM, Sho M, Sho E., McConnell MV, Dalman RL Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression. Arterioscler Thromb Vasc Biol. 2009; 29:1452-1457.
6. Kitagawa T, Kosuge H, Uchida M., Dua MM, Iida Y, Dalman RL, Douglas T, McConnell MV RGD-conjugated human ferritin nanoparticles for imaging vascular inflammation and angiogenesis in experimental carotid and aortic disease. Mol Imaging Biol. 2012; 14:315-324.
7. Paik DC, Fu C, Bhattacharya J., Tilson MD Ongoing angiogen-esis in blood vessels of the abdominal aortic aneurysm. Exp Mol Med. 2004; 36:524-533.
8. Choke E, Thompson MM, Dawson J, Wilson W.R., Sayed S., Loftus IM, Cockerill GW Abdominal aortic aneurysm rupture is associated with increased medial neovascularization and overexpression of proangiogenic cytokines. Arterioscler Thromb Vasc Biol. 2006; 26:2077-2082.
9. Hoshiga M, Alpers CE, Smith L.L., Giachelli CM, Schwartz SM Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. Circ Res. 1995; 77:1129-1135.
10. Antonov AS, Kolodgie FD, Munn D.H., Gerrity RG Regulation of macrophage foam cell formation by alphaVbeta3 integrin: potential role in human atherosclerosis. Am J Pathol. 2004; 165:247-258.
11. Haubner R, Wester HJ Radiolabeled tracers for imaging of tumor angio-genesis and evaluation of anti-angiogenic therapies. Curr Pharm Des. 2004; 10:1439-1455.
12. Chen X. Multimodality imaging of tumor integrin alphavbeta3 expression. Mini Rev Med Chem. 2006; 6:227-234.
13. Chen X, Tohme M, Park R., Hou Y, Bading JR, Conti PS Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging. 2004; 3:96-104.
14. Zhang X, Xiong Z, Wu Y., Cai W, Tseng JR, Gambhir S.S., Chen X. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med. 2006; 47:113-121.
15. Liu S, Liu Z, Chen K., Yan Y, Watzlowik P, Wester H.J., Chin FT, Chen X. 18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol. 2010; 12:530-538.
16. Mittra ES, Goris ML, Iagaru A.H., Kardan A., Burton L, Berganos R, Chang E., Liu S, Shen B, Chin F.T., Chen X., Gambhir SS Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. Radiology. 2011; 260:182-191.
17. 2): an automated multi-step radiosynthesis for clinical PET studies. Mol Imaging Biol. 2012; 14:88-95.
18. Chang E, Liu S, Gowrishankar G., Yaghoubi S, Wedgeworth JP, Chin F, Berndorff D., Gekeler V, Gambhir SS, Cheng Z. Reproducibility study of [(18)F]FPP(RGD)2 uptake in murine models of human tumor xenografts. Eur J Nucl Med Mol Imaging. 2011; 38:722-730.
19. Daugherty A, Manning MW, Cassis LA Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000; 105:1605-1612.
20. Tseng JR, Dandekar M, Subbarayan M., Cheng Z, Park JM, Louie S, Gambhir SS Reproducibility of 3'-deoxy-3'-(18)F-fluorothymidine microPET studies in tumor xenografts in mice. J Nucl Med. 2005; 46:1851-1857.
21. Winter PM, Morawski AM, Caruthers S.D., Fuhrhop RW, Zhang H, Williams TA, Allen J.S., Lacy EK, Robertson JD, Lanza GM, Wickline SA Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation. 2003; 108:2270-2274.
22. Laitinen I, Saraste A, Weidl E., Poethko T, Weber AW, Nekolla S.G., Leppänen P, Ylä-Herttuala S, Hölzlwimmer G, Walch A, Esposito I, Wester HJ, Knuuti J, Schwaiger M. Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. Circ Cardiovasc Imaging. 2009; 2:331-338.
23. Metz S, Ganter C, Lorenzen S., van Marwick S, Herrmann K, Lordick F., Nekolla SG, Rummeny EJ, Wester HJ, Brix G, Schwaiger M., Beer AJ Phenotyping of tumor biology in patients by multimodality multiparamet-ric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism. J Nucl Med. 2010; 51:1691-1698.
24. Nahrendorf M, Keliher E, Marinelli B., Leuschner F, Robbins CS, Gerszten R.E., Pittet MJ, Swirski FK, Weissleder R. Detection of macrophages in aortic aneurysms by nanoparticle positron emission tomography-computed tomography. Arterioscler Thromb Vasc Biol. 2011; 31:750-757.
25. Reeps C, Essler M, Pelisek J., Seidl S, Eckstein HH, Krause BJ Increased 18F-fluorodeoxyglucose uptake in abdominal aortic aneurysms in positron emission/computed tomography is associated with inflammation, aortic wall instability, and acute symptoms. J Vasc Surg. 2008; 48:417-423.
26. Kotze CW, Menezes LJ, Endozo R, Groves A.M., Ell PJ, Yusuf SW Increased metabolic activity in abdominal aortic aneurysm detected by 18F- fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT). Eur J Vasc Endovasc Surg. 2009; 38:93-99.
27. 18F-FDG aortic aneurysm uptake on PET/CT and future growth rate? Eur J Nucl Med Mol Imaging. 2011; 38:1493-1499.
28. Gambhir SS; Stanford University. Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2. In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2013 Jan 13]. Available from: http://clinicaltrials.gov/show/NCT01383135 NLM Identifier: NCT01383135.